Related Experiment Video
Updated: May 6, 2026
Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based on the VIM and CDH2 protein
Junkai Qin1, Kecheng Liao1, Lu Huang2
1Department of Urology, Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning 530001, China.
Abstract:
Bladder cancer progression is intrinsically linked to epithelial-mesenchymal transition (EMT), a protein-centric process driving metastasis and therapy resistance. This study systematically dissected bladder cancer transcriptomes through the lens of VIM (vimentin) and CDH2 (N-cadherin) protein networks, integrating datasets from GEO via cross-platform harmonization. Non-negative matrix factorization (NMF) resolved two molecular subtypes with distinct EMT-related protein expression profiles, characterized by asymmetric transcriptomic dysregulation. Functional enrichment revealed protein-driven pathways-including TGF-β signaling, Wnt/β-catenin activation, and ECM remodeling-as hallmarks of aggressive subtypes. LASSO regression identified 384 transcriptional drivers, while PPI network analysis prioritized 10 hub proteins (CALML5, THBS1, SMAD7, TAGLN, ICAM1, CEBPB, CNN1, TNFAIP3, TNFRSF1A, EFEMP2) via maximum clique centrality (MCC). Critically, TAGLN, CNN1, THBS1, and SMAD7 exhibited significant co-expression with VIM and CDH2 (correlation coefficients >0.1), implicating their roles in cytoskeletal protein assembly (TAGLN, CNN1), matricellular signaling (THBS1), and TGF-β pathway regulation (SMAD7). Functional validation confirmed these hub proteins as central to EMT plasticity, with TAGLN-VIM/CDH2 co-activation (r = 0.55 and 0.24, respectively) driving actin polymerization and protein-mediated invasion. SMAD7 further modulated TNFRSF1A-TNFAIP3 crosstalk to sustain mesenchymal phenotypes. This multi-omics framework delineates VIM/CDH2-centric protein interactomes as therapeutic vulnerabilities, proposing TAGLN/THBS1-targeted strategies to disrupt EMT-driven metastasis. By anchoring molecular subtyping and drug discovery in protein network topology, this work advances precision oncology for bladder cancer, bridging transcriptomic heterogeneity to actionable protein targets.
Insights
Bladder cancer progression involves epithelial-mesenchymal transition (EMT). This study identified key protein networks and therapeutic targets, like TAGLN and THBS1, to disrupt metastasis and improve precision oncology.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Bladder cancer progression is driven by epithelial-mesenchymal transition (EMT), a process linked to metastasis and treatment resistance.
- Vimentin (VIM) and N-cadherin (CDH2) protein networks are central to EMT in bladder cancer.
Purpose of the Study:
- To systematically analyze bladder cancer transcriptomes focusing on VIM and CDH2 protein networks.
- To identify molecular subtypes, key protein drivers, and potential therapeutic targets for bladder cancer progression.
Main Methods:
- Integrated GEO datasets using cross-platform harmonization.
- Applied Non-negative Matrix Factorization (NMF) for molecular subtyping.
- Utilized LASSO regression and Protein-Protein Interaction (PPI) network analysis with Maximum Clique Centrality (MCC).
Main Results:
- Identified two molecular subtypes with distinct EMT-related protein profiles and transcriptomic dysregulation.
- Prioritized 10 hub proteins, including TAGLN, CNN1, THBS1, and SMAD7, showing significant co-expression with VIM/CDH2.
- Validated TAGLN-VIM/CDH2 co-activation's role in actin polymerization and invasion; SMAD7 modulated TNFRSF1A-TNFAIP3 crosstalk.
Conclusions:
- VIM/CDH2-centric protein interactomes represent therapeutic vulnerabilities in bladder cancer.
- TAGLN and THBS1-targeted strategies may disrupt EMT-driven metastasis.
- This multi-omics approach links transcriptomic heterogeneity to actionable protein targets for precision oncology.
